LON:HIK - Hikma Pharmaceuticals Share Price, Forecast & News

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

Hikma Pharmaceuticals declared a dividend on Friday, August 9th. Investors of record on Thursday, August 22nd will be given a dividend of GBX 0.14 per share on Monday, September 23rd. This represents a yield of 0.59%. The ex-dividend date of this dividend is Thursday, August 22nd. The official announcement can be seen at this link. View Hikma Pharmaceuticals' Dividend History.

Hikma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Hikma Pharmaceuticals.

8 analysts have issued 1 year target prices for Hikma Pharmaceuticals' shares. Their forecasts range from GBX 1,350 to GBX 2,240. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 1,853.33 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for Hikma Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals.

Media coverage about HIK stock has been trending positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Hikma Pharmaceuticals.

Some companies that are related to Hikma Pharmaceuticals include Merck KGaA (MRK), Bausch Health Companies (BHC), Canopy Growth (WEED), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), ORGANIGRAM-TS (OGI), Hexo (HEXO), Next Science (NXS), HEXO (HEXO) and Benchmark (BMK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of HIK stock can currently be purchased for approximately GBX 1,942.50.

Hikma Pharmaceuticals has a market capitalization of £4.71 billion and generates £2.14 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe.View Additional Information About Hikma Pharmaceuticals.

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.